Papilloma Pipeline Analysis Report 2025
Description
Papilloma refers to a benign growth caused by the human papillomavirus (HPV), which is also the leading cause of cervical cancer. Every two minutes, a woman dies from cervical cancer, with global cases rising alarmingly. Despite routine HPV vaccinations preventing most cases, a high unmet clinical need for advanced therapies persists. Current treatment options, such as surgery or cryotherapy, are often invasive and limited. However, the growing focus on immunotherapies, targeted treatments, and antiviral drugs is set to drive pipeline development. These advancements aim to provide safer, more effective solutions to combat human papillomavirus-related diseases, addressing this critical global health challenge.
Report Coverage
The Papilloma Pipeline Insight Report by Expert Market Research gives comprehensive insights into papilloma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for papilloma. The papilloma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The papilloma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with papilloma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to papilloma.
Papilloma Pipeline Outlook
Papilloma refers to growths caused by the human papillomavirus (HPV), which infects epithelial cells, leading to benign tumors. HPV is transmitted through skin-to-skin contact, and while most infections resolve on their own, some can lead to cervical, anal, or throat cancers. The drug pipeline is focused on developing antivirals, immune-based therapies, and vaccines to prevent and treat HPV-related diseases.
Papilloma treatments include cryotherapy, surgical removal, and laser therapy, which target visible warts. For cervical papilloma, HPV vaccines like Gardasil offer prevention. Antiviral treatments and immune therapies are also being explored to target the virus and reduce recurrence, offering more comprehensive management for patients. In January 2025, the U.S. Food and Drug Administration granted orphan drug designation to pembrolizumab, a PD-1 checkpoint inhibitor, for treating recurrent respiratory papillomatosis.
Papilloma Epidemiology
The papilloma pipeline addresses the increasing global burden of human papillomavirus-related diseases. In Eastern Europe and Southeast Asia, the prevalence of cervical HPV among women has reached 14%. In India, over 80% of sexually active women are likely to acquire genital HPV by age 50. In the United States, from 2017 to 2021, approximately 47,984 new HPV-associated cancer cases were reported annually. These statistics highlight the urgent need for innovative therapies.
Papilloma Pipeline Therapeutic Assessment
This section of the report covers the analysis of papilloma drug candidates based on several segmentations, including:
By Phase
The pipeline report covers 50+ drug analyses based on phase:
The papilloma pipeline analysis report covers 50+ drug analyses based on drug classes:
The papilloma assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 48.21%, covers a major share of the total papilloma clinical trials. It is followed by phase I at 23.21%, phase IV at 14.29%, phase III at 8.93%, and early phase I at 5.36%. This strong focus on mid-stage development highlights significant progress in papilloma research. Advancements across all phases are expected to impact the papilloma market with innovative treatment options positively.
Papilloma – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the papilloma pipeline analysis include small molecules, monoclonal antibodies, vaccines, and immunotherapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for papilloma. Small molecule inhibitors targeting the human papillomavirus (HPV) E5 oncogene protein are gaining attention in the papilloma pipeline. For instance, TGN-S11 by Toragen, Inc. is under Phase 1 investigation as both a monotherapy and in combination with pembrolizumab. It has demonstrated early signs of antitumor activity and safety, supporting further clinical development for HPV-associated cancers.
Papilloma Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR papilloma pipeline report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Papilloma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging papilloma drugs. It includes product description, trial ID, study type, drug class, administration mode, and papilloma drug candidates' recruitment status.
Drug: 2LPAPIA
The Phase 4 study, sponsored by Labo'Life, aims to evaluate the efficacy of 2LPAPI® in clearing genital high-risk HPV (HR-HPV) infections. This placebo-controlled trial includes an estimated 284 participants and spans a 72-month duration. The study began on October 17, 2020, and is expected to be completed by October 30, 2027, with primary results anticipated by March 2027.
Drug: PRGN-2012
Precigen, Inc. is sponsoring a Phase 3 confirmatory study to assess the efficacy and safety of PRGN-2012 for treating recurrent respiratory papillomatosis (RRP) in adults. This single-arm, open-label trial involves about 42 participants with a history of repeated surgical debulking. The study began on July 11, 2024, and is estimated to complete primary evaluation by March 2027, with completion by March 2029.
Drug: Lenti-HPV-07
The clinical trial, sponsored by Theravectys S.A., aims to evaluate the safety, immunogenicity, and preliminary efficacy of Lenti-HPV-07 immunotherapy for HPV-associated cervical and oropharyngeal cancers. The objective of this Phase 1/2a study is to assess whether Lenti-HPV-07 induces an immune response and its safety profile. The study is expected to be completed by December 2026, with around 72 participants enrolled.
Key Questions Answered in the Papilloma – Pipeline Insight Report
The Papilloma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for papilloma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into papilloma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Human Papillomavirus (HPV) Drug Pipeline
Global Human Papillomavirus (HPV) Vaccine Market
Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline
Global Clinical Trials Market
Report Coverage
The Papilloma Pipeline Insight Report by Expert Market Research gives comprehensive insights into papilloma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for papilloma. The papilloma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The papilloma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with papilloma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to papilloma.
Papilloma Pipeline Outlook
Papilloma refers to growths caused by the human papillomavirus (HPV), which infects epithelial cells, leading to benign tumors. HPV is transmitted through skin-to-skin contact, and while most infections resolve on their own, some can lead to cervical, anal, or throat cancers. The drug pipeline is focused on developing antivirals, immune-based therapies, and vaccines to prevent and treat HPV-related diseases.
Papilloma treatments include cryotherapy, surgical removal, and laser therapy, which target visible warts. For cervical papilloma, HPV vaccines like Gardasil offer prevention. Antiviral treatments and immune therapies are also being explored to target the virus and reduce recurrence, offering more comprehensive management for patients. In January 2025, the U.S. Food and Drug Administration granted orphan drug designation to pembrolizumab, a PD-1 checkpoint inhibitor, for treating recurrent respiratory papillomatosis.
Papilloma Epidemiology
The papilloma pipeline addresses the increasing global burden of human papillomavirus-related diseases. In Eastern Europe and Southeast Asia, the prevalence of cervical HPV among women has reached 14%. In India, over 80% of sexually active women are likely to acquire genital HPV by age 50. In the United States, from 2017 to 2021, approximately 47,984 new HPV-associated cancer cases were reported annually. These statistics highlight the urgent need for innovative therapies.
Papilloma Pipeline Therapeutic Assessment
This section of the report covers the analysis of papilloma drug candidates based on several segmentations, including:
By Phase
The pipeline report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
The papilloma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Vaccines
- Immunotherapies
The papilloma assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 48.21%, covers a major share of the total papilloma clinical trials. It is followed by phase I at 23.21%, phase IV at 14.29%, phase III at 8.93%, and early phase I at 5.36%. This strong focus on mid-stage development highlights significant progress in papilloma research. Advancements across all phases are expected to impact the papilloma market with innovative treatment options positively.
Papilloma – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the papilloma pipeline analysis include small molecules, monoclonal antibodies, vaccines, and immunotherapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for papilloma. Small molecule inhibitors targeting the human papillomavirus (HPV) E5 oncogene protein are gaining attention in the papilloma pipeline. For instance, TGN-S11 by Toragen, Inc. is under Phase 1 investigation as both a monotherapy and in combination with pembrolizumab. It has demonstrated early signs of antitumor activity and safety, supporting further clinical development for HPV-associated cancers.
Papilloma Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR papilloma pipeline report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Papilloma clinical trials:
- Labo'Life
- Catalysis SL
- Theravectys S.A.
- Precigen, Inc.
- BioNTech SE
- BlueSky Immunotherapies GmbH
- NexImmune Inc.
- TScan Therapeutics, Inc.
- SCG Cell Therapy Pte. Ltd.
- Merck Sharp & Dohme LLC
- Eisai Inc.
- Atika Pharma S.L.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging papilloma drugs. It includes product description, trial ID, study type, drug class, administration mode, and papilloma drug candidates' recruitment status.
Drug: 2LPAPIA
The Phase 4 study, sponsored by Labo'Life, aims to evaluate the efficacy of 2LPAPI® in clearing genital high-risk HPV (HR-HPV) infections. This placebo-controlled trial includes an estimated 284 participants and spans a 72-month duration. The study began on October 17, 2020, and is expected to be completed by October 30, 2027, with primary results anticipated by March 2027.
Drug: PRGN-2012
Precigen, Inc. is sponsoring a Phase 3 confirmatory study to assess the efficacy and safety of PRGN-2012 for treating recurrent respiratory papillomatosis (RRP) in adults. This single-arm, open-label trial involves about 42 participants with a history of repeated surgical debulking. The study began on July 11, 2024, and is estimated to complete primary evaluation by March 2027, with completion by March 2029.
Drug: Lenti-HPV-07
The clinical trial, sponsored by Theravectys S.A., aims to evaluate the safety, immunogenicity, and preliminary efficacy of Lenti-HPV-07 immunotherapy for HPV-associated cervical and oropharyngeal cancers. The objective of this Phase 1/2a study is to assess whether Lenti-HPV-07 induces an immune response and its safety profile. The study is expected to be completed by December 2026, with around 72 participants enrolled.
Key Questions Answered in the Papilloma – Pipeline Insight Report
- What is the current landscape of papilloma pipeline drugs?
- Which companies/institutions are developing papilloma emerging drugs?
- How many phase II drugs are currently present in papilloma pipeline drugs?
- Which company is leading the papilloma pipeline development activities?
- What is the current papilloma therapeutic assessment?
- What are the opportunities and challenges present in the papilloma pipeline landscape?
- What is the efficacy and safety profile of papilloma pipeline drugs?
- Which companies/institutions are involved in papilloma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in papilloma?
The Papilloma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for papilloma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into papilloma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Human Papillomavirus (HPV) Drug Pipeline
Global Human Papillomavirus (HPV) Vaccine Market
Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Papilloma
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Papilloma
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Papilloma: Epidemiology Snapshot
- 5.1 Papilloma Incidence by Key Markets
- 5.2 Papilloma – Patients Seeking Treatment in Key Markets
- 6 Papilloma: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Papilloma: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Papilloma, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Papilloma Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Papilloma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: 2LPAPIÂ
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: PRGN-2012
- 10.2.3 Other Drugs
- 11 Papilloma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Lenvatinib
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: 9-Valent HPV Vaccination
- 11.2.3 Other Drugs
- 12 Papilloma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: Fludarabine
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Papilloma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Papilloma, Key Drug Pipeline Companies
- 14.1 Labo'Life
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Catalysis SL
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Theravectys S.A.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Precigen, Inc.,
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 BioNTech SE
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 BlueSky Immunotherapies GmbH
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 NexImmune Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 TScan Therapeutics, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 SCG Cell Therapy Pte. Ltd.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Merck Sharp & Dohme LLC
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Eisai Inc.
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 14.12 Atika Pharma S.L.
- 14.12.1 Company Snapshot
- 14.12.2 Pipeline Product Portfolio
- 14.12.3 Financial Analysis
- 14.12.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
